More than 90% of patients achieved clinically meaningful weight reduction compared to placebo in a phase 3 trial of ecnoglutide.

A novel weight loss drug in the same class as semaglutide has successfully met its targets in its largest clinical trial yet, ...

In June 2025, Carmot Therapeutics Inc. announced a Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of ...

GLP-1 drugs such as Wegovy and Zepbound are growing increasingly prominent. But some food ingredients can also cause the body ...

If you’re considering using medication to reach a healthy body weight, your first question might be: Are weight loss drugs covered by insurance? The short answer: Sometimes, but not always.

A recent study found that older adults with diabetes who use a GLP-1 drug have double the risk of developing wet age-related ...

Compounded vs non-compounded GLP-1 RA drug products are associated with an increased risk for adverse events such as nausea and diarrhea.

A new study reports that people taking GLP-1 drugs in daily life don’t lose as much weight as those in clinical trials who ...

GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

A new obesity drug combining four hormones may outperform Wegovy and Mounjaro. Learn what it means for health, science, and investors.

Ozempic is an FDA-approved medication for people with type 2 diabetes. It’s often prescribed off-label for weight loss — that ...

Discover how GLP-1 drugs are driving demand for new supplements. Insights from Vitafoods Europe 2025 reveal how the industry ...